Browsing by Yonsei Author : Lee, Jung-Yun

eperson profile image
Name :
Lee, Jung-Yun [이정윤]
orcid http://orcid.org/0000-0001-7948-1350
Department :
College of Medicine (의과대학) - Dept. of Obstetrics and Gynecology (산부인과학교실)
Scopus ID :
Scopus (56191369600)

교수 기본정보

세부 전공
부인종양학
이메일
jungyunlee@yuhs.ac

실험실 기본정보

이름
GLORY연구팀
위치
ABMRC 517호
구분
Wet Lab (50%), Dry Lab (50%)

연구소개

연구 분야
연구 내용
▷ 본 연구실은 연세대학교 의과대학 산부인과학교실의 부인종양전문가인 이정윤 교수님, 이용재 교수님, 박준식 교수님께서 함께 운영하고 있으며, 다국적 제약사의 초기개발단계 약제를 이용하여 난소암 영역에서 연구자주도임상시험을 진행하고 있는 국내 유일의 연구팀으로써 임상시험을 통하여 획득한 환자 유래 검체(조직, 혈액)를 이용하여 신약의 바이오마커 및 내성 기전을 규명하는 중개 연구를 진행하고 있습니다. 난치성 부인암 환자들에게 새로운 신약 치료의 기회를 제공해 줄 수 있는 다양한 임상시험을 주도하는 동시에, 임상시험 및 수술을 통하여 수집된 환자 유래 검체 (조직, 혈액)를 이용한 중개 연구를 수행하고 있습니다. 본 연구팀은 임상연구와 중개 연구를 통하여 정밀 의료의 적용과 부인암 환자들의 생존율 향상에 도움이 될 수 있는 치료법 개발을 위하여 노력하고 있습니다.
▷ 부인암 환자들은 다양한 치료 (수술, 고전적 항암, 면역치료, 표적 치료, 방사선 치료)를 받고 있기 때문에 치료법, 치료 시기에 따른 연구가 중요합니다. 본 연구실에서는 임상 연구 결과뿐만 아니라, 이 결과들을 설명할 수 있는 이론적 근거를 중개 연구를 통해 규명하고자 노력하고 있습니다. 반대로 중개연구 결과를 바탕으로 새로운 치료 전략을 수립하고 이를 임상에 적용하고자 노력합니다. 이렇게 임상연구와 중개 연구를 유기적으로 연계하여 총체적인 연구를 수행하고 있고, 임상정보부터 유전체, 전사체, 그리고 면역 분석 정보까지 다양한 연구 데이터베이스를 활용하고 있습니다. 이러한 결과들을 다수의 국제 학술 대회에서 발표하고, 많은 SCI(E) 학술 논문을 출판하고 있습니다.
▷ 최근에는 부인암의 세부 암종에 따른 특성 차이와 부인암 환자의 치료 경과에 따른 종양주위미세환경의 변화를 탐색하고 수술 및 약물 치료 과정에서 순차적으로 얻어진 조직 및 혈액의 특성을 분석하는 등 다양한 활발한 연구를 진행하고 있습니다.

학생 참여 정보

학생들이 참여하면 좋을 연구
  • ▷ 부인암 환자유래 조직 및 혈액의 유세포 분석을 통한 면역학적 특성 규명연구
  • a)부인암 환자의 혈액내 면역세포, 종양침윤 면역세포의 분리
  • b)시계열적으로 수집된 종양침윤 면역세포의 특성 및 기능의 변화를 세포면역학적 기법으로 분석 (유세포 분석기 활용)
  • c)혈액 검체 기반, 순환종양세포에서 검출된 종양의 유전체 및 전사체 기반 중개연구
  • ▷ 난소암 표적항암제 저항성 조직 및 혈액의 내성기전 규명 및 극복방안 연구 (유전체 분석 과정 참여)
  • ▷ 난소암 중 rare histology 에 대한 면역학적 특성 규명 및 논문 작성
  • ▷ 연구자 주도 임상 시험 디자인 및 실제 다국적제약사에 연구 제안서 제출
학생 참여 시 사용하게 되는 장비 및 프로그램
  • Flow cytometry, R software, SPSS, Flowjo software
참여 전 준비사항
  • 관심있는 분야에 대한 탐색, 면역학 기초 지식 (교과서 수준), 기초적인 통계 지식

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 215

This table browses all dspace content
Issue DateTitleJournal Title
2025Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma CELL REPORTS MEDICINE
2025A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients BRITISH JOURNAL OF CANCER
2025Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation JOURNAL OF CLINICAL ONCOLOGY
2025AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancerGYNECOLOGIC ONCOLOGY
2025Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and PlasmaCLINICAL CANCER RESEARCH
2025Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02ADVANCES IN THERAPY
2025A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC) JOURNAL OF GYNECOLOGIC ONCOLOGY
2025Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical TrialCLINICAL CANCER RESEARCH
2025Impact of clinical trial participation on the survival of patients with newly diagnosed advanced ovarian cancer FRONTIERS IN ONCOLOGY
2025Patient-reported outcomes from the MIRASOLtrial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trialLANCET ONCOLOGY
2025Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8+ T cells JOURNAL FOR IMMUNOTHERAPY OF CANCER
2025Is presumed clinical stage I endometrial cancer using PET-CT and MRI accurate in predicting surgical staging? JOURNAL OF GYNECOLOGIC ONCOLOGY
2025Morbidity and Mortality Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer JOURNAL OF CLINICAL MEDICINE
2025The Association Between Location of BRCA Mutation and Efficacy of PARP Inhibitor as a Frontline Maintenance Therapy in Advanced Epithelial Ovarian Cancer CANCERS
2025Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines JOURNAL OF GYNECOLOGIC ONCOLOGY
2025Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80) JOURNAL OF GYNECOLOGIC ONCOLOGY
2025Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers JOURNAL OF GYNECOLOGIC ONCOLOGY
2024Mismatch repair, p53, and L1 cell adhesion molecule status influence the response to chemotherapy in advanced and recurrent endometrial cancer BMC CANCER
2024Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 ADVANCES IN THERAPY
2024A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2024Changes in the tumor immune microenvironment during disease progression in clear cell ovarian cancerINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2024Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapyJOURNAL OF GYNECOLOGIC ONCOLOGY
2024Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialLANCET
2024Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled TrialJAMA ONCOLOGY
2024Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical TrialOBSTETRICAL & GYNECOLOGICAL SURVEY
2024Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 BlockadeCLINICAL CANCER RESEARCH
2024OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer FUTURE ONCOLOGY
2024Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysisGYNECOLOGIC ONCOLOGY
2024Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8 + TILs based on BRCA1/2 mutation status in epithelial ovarian cancers JOURNAL FOR IMMUNOTHERAPY OF CANCER
2024Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical CancerNEW ENGLAND JOURNAL OF MEDICINE
2024Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer NATURE COMMUNICATIONS
2024Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trialLANCET
2024RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer FRONTIERS IN ONCOLOGY
2024Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer SCIENTIFIC REPORTS
2024The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation JOURNAL OF GYNECOLOGIC ONCOLOGY
2024Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trialGYNECOLOGIC ONCOLOGY
2024Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic FactorAMERICAN JOURNAL OF SURGICAL PATHOLOGY
2024Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study FRONTIERS IN IMMUNOLOGY
2024Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer JOURNAL OF GYNECOLOGIC ONCOLOGY
2024Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045INTERNATIONAL JOURNAL OF CANCER
2024Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125GYNECOLOGIC ONCOLOGY
2024Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian CancerCANCER RESEARCH
2024Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial JOURNAL OF CLINICAL ONCOLOGY
2024Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines JOURNAL OF GYNECOLOGIC ONCOLOGY
2024Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial JOURNAL OF CLINICAL ONCOLOGY
2023Initial experience with the da Vinci SP robot-assisted surgical staging of endometrial cancer: a retrospective comparison with conventional laparotomyJOURNAL OF ROBOTIC SURGERY
2023Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian CancerNEW ENGLAND JOURNAL OF MEDICINE
2023Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer SCIENTIFIC REPORTS
2023Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trialLANCET ONCOLOGY
2023Secondary cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer GLAND SURGERY

Browse

Links